Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.

Lorusso, Patricia M; Jimeno, Antonio; Dy, Grace; Adjei, Alex; Berlin, Jordan; Leichman, Lawrence; Low, Jennifer A; Colburn, Dawn; Chang, Ilsung; Cheeti, Sravanthi; Jin, Jin Y; Graham, Richard A

Lorusso, Patricia M; Jimeno, Antonio; Dy, Grace; Adjei, Alex; Berlin, Jordan; Leichman, Lawrence; Low, Jennifer A; Colburn, Dawn; Chang, Ilsung; Cheeti, Sravanthi; Jin, Jin Y; Graham, Richard A.

Affiliation

Lorusso PM; Karmanos Cancer Institute, Detroit, Michigan, USA.

Clin Cancer Res ; 17(17): 5774-82, 2011 Sep 01.

Article in En | MEDLINE | ID: mdl-21753154

Subject(s)

Anilides/administration & dosage; Anilides/pharmacokinetics; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/pharmacokinetics; Hedgehog Proteins/antagonists & inhibitors; Neoplasms/drug therapy; Pyridines/administration & dosage; Pyridines/pharmacokinetics; Anilides/adverse effects; Anilides/therapeutic use; Antineoplastic Agents/adverse effects; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Neoplasms/pathology; Pyridines/adverse effects; Pyridines/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Hedgehog Proteins / Anilides / Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2011 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google